GSK plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Luke Victor Miels
- Full Time Employees
- 66,841
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 79 New Oxford Street London GL United Kingdom WC1A 1DG
- IPO Date
- Mar 28, 1980
- CIK
- 0001131399
- Website
- gsk.com
- Similar Companies
- Business
- GSK plc is a British multinational biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and specialty therapies focused on respiratory/immunology, oncology, HIV and infectious diseases. Founded through the 2000 merger of Glaxo Wellcome and SmithKline Beecham with origins tracing to 1715, the company is headquartered at 79 New Oxford Street in London, England, and operates globally with manufacturing sites in 37 countries, delivering products to markets including the US, Europe, Asia and emerging regions. Its core portfolio encompasses specialty medicines such as Nucala (mepolizumab) for severe eosinophilic asthma, COPD and CRSwNP; Jemperli (dostarlimab) for endometrial cancer; Blenrep (belantamab mafodotin) for multiple myeloma; Arexvy and Shingrix vaccines for RSV and shingles respectively; a broad range of over 20 vaccines targeting meningococcal disease (e.g. Penmenvy, a 5-in-1 MenABCWY vaccine), HPV, hepatitis and influenza; HIV treatments via ViiV Healthcare including long-acting injectables like Cabenuva (cabotegravir + rilpivirine), Apretude for PrEP and investigational assets like N6LS; general medicines including inhalers for asthma/COPD, antibiotics and gepotidacin (Blujepa) for UTIs; and oncology offerings like Zejula (niraparib) for ovarian cancer. In recent developments, GSK completed the $1.15 billion acquisition of IDRx Inc. in 2025 to advance IDRX-42, a next-generation KIT inhibitor for GIST adding to its GI cancer portfolio; entered a potential $12 billion alliance with Hengrui Pharma paying $500 million upfront for rights to a COPD candidate and up to 11 respiratory, immunology and oncology programs outside greater China; acquired exclusive rights from Syndivia for a prostate cancer antibody-drug conjugate; launched or gained approvals for five new products/line extensions in 2025 including Penmenvy, Blujepa, Nucala for COPD and depemokimab (under FDA/EMA review as the first 6-month ultra-long-acting biologic for type 2 asthma and CRSwNP); announced a $30 billion US investment over five years including a $1.2 billion biologics facility in Pennsylvania; established the GSK-Oxford Cancer Immuno-Prevention Programme; and relocated its headquarters to central London while preparing for CEO transition to Luke Miels in 2026.
Company News
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
GSK retains ‘buy' rating at Jefferies as B7H3 cancer programme seen as underappreciated
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care
GSK plc (GSK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
GSK strikes up to $750 million deal for cancer-targeting drug
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy